Stable latent HIV infection and low-level viremia despite treatment with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent vorinostat
CL Gay, KS James, M Tuyishime… - The Journal of …, 2022 - academic.oup.com
We tested the combination of a broadly neutralizing HIV antibody with the latency reversal
agent vorinostat (VOR). Eight participants received 2 month-long cycles of VRC07-523LS …
agent vorinostat (VOR). Eight participants received 2 month-long cycles of VRC07-523LS …
[HTML][HTML] Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection
CL Gay, JD Kuruc, SD Falcinelli, JA Warren… - Scientific Reports, 2020 - nature.com
Approaches to deplete persistent HIV infection are needed. We investigated the combined
impact of the latency reversing agent vorinostat (VOR) and AGS-004, an autologous …
impact of the latency reversing agent vorinostat (VOR) and AGS-004, an autologous …
Effect of HIV antibody VRC01 on viral rebound after treatment interruption
KJ Bar, MC Sneller, LJ Harrison… - … England Journal of …, 2016 - Mass Medical Soc
Background The discovery of potent and broadly neutralizing antibodies (bNAbs) against
human immunodeficiency virus (HIV) has made passive immunization a potential strategy …
human immunodeficiency virus (HIV) has made passive immunization a potential strategy …
[HTML][HTML] Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency
NM Archin, JL Kirchherr, JAM Sung… - The Journal of …, 2017 - Am Soc Clin Investig
BACKGROUND. The histone deacetylase (HDAC) inhibitor vorinostat (VOR) can increase
HIV RNA expression in vivo within resting CD4+ T cells of aviremic HIV+ individuals …
HIV RNA expression in vivo within resting CD4+ T cells of aviremic HIV+ individuals …
The effects of human immunodeficiency virus type 1 (HIV-1) antigen-expanded specific T-cell therapy and vorinostat on persistent HIV-1 infection in people with HIV …
CL Gay, PJ Hanley, SD Falcinelli… - The Journal of …, 2024 - academic.oup.com
Background The histone deacetylase inhibitor vorinostat (VOR) can reverse human
immunodeficiency virus type 1 (HIV-1) latency in vivo and allow T cells to clear infected cells …
immunodeficiency virus type 1 (HIV-1) latency in vivo and allow T cells to clear infected cells …
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
Passive immunization with HIV-1–neutralizing monoclonal antibodies (mAbs) is being
considered for prevention and treatment of HIV-1 infection. As therapeutic agents, mAbs …
considered for prevention and treatment of HIV-1 infection. As therapeutic agents, mAbs …
Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART
Background Broadly neutralizing monoclonal antibodies (bnMAbs) may promote clearance
of HIV-1-expressing cells through antibody-dependent cell-mediated cytotoxicity. We …
of HIV-1-expressing cells through antibody-dependent cell-mediated cytotoxicity. We …
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial
TA Crowell, DJ Colby, S Pinyakorn, C Sacdalan… - The lancet HIV, 2019 - thelancet.com
Background HIV-1-specific broadly neutralising antibodies such as VRC01 could promote
HIV remission by halting viral replication and clearing infected cells. We investigated …
HIV remission by halting viral replication and clearing infected cells. We investigated …
[HTML][HTML] Vorinostat renders the replication-competent latent reservoir of human immunodeficiency virus (HIV) vulnerable to clearance by CD8 T cells
JA Sung, K Sholtis, J Kirchherr, JD Kuruc, CL Gay… - …, 2017 - thelancet.com
Latently human immunodeficiency virus (HIV)-infected cells are transcriptionally quiescent
and invisible to clearance by the immune system. To demonstrate that the latency reversing …
and invisible to clearance by the immune system. To demonstrate that the latency reversing …
[HTML][HTML] Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
EM Cale, H Bai, M Bose, MA Messina… - The Journal of …, 2020 - Am Soc Clin Investig
Infusion of the broadly neutralizing antibody VRC01 has been evaluated in individuals
chronically infected with HIV-1. Here, we studied how VRC01 infusions affected viral …
chronically infected with HIV-1. Here, we studied how VRC01 infusions affected viral …